Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
Sponsor: Astellas Pharma Inc
A PHASE3 clinical study on Myocardial Ischemia, this trial is completed. The trial is conducted by Astellas Pharma Inc and has accumulated 8 data snapshots since 1998. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- AstraZeneca
- Bristol-Myers Squibb
- Datascope Corp.
- First Horizon
- GE Healthcare
- Hoest-Marion-Roussel
- Integrated Therapeutics Group
- Key Pharmaceuticals
- Kos
- Medical Research Council of Canada
- Merck Sharp & Dohme LLC
- Pfizer
- Sanofi
- US Department of Veterans Affairs
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States, Ann Arbor, United States, Baltimore, United States, Boston, United States, Calgary, Canada, Chicago, United States, Cleveland, United States, Davenport, United States, Decatur, United States, Detroit, United States and 34 more location s